Cost-effectiveness of riociguat and bosentan for the treatment of chronic thromboembolic pulmonary hypertension
OBJECTIVE: To conduct a cost-effectiveness analysis of riociguat and bosentan in the management of chronic thromboembolic pulmonary hypertension (CTEPH) from a United States payer perspective. METHODS: A Markov model was developed following the recommendations of the International Society of Pharma...
| Main Author: | |
|---|---|
| Language: | en_US |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/27101 |